Sangamo Therapeutics lost two powerhouse partners Friday after it reported that both Novartis and Biogen discontinued focusing on gene regulation therapies in the neurology space.
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo Read More »
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3 Read More »
Dante Genomics , a global leader in genomics and precision medicine, launched today the beta version of Avanti, the Company’s proprietary B2B software for variant interpretation and report writing at scale.
Karuna Therapeutics, Inc. announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia.
Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division, has just started to commercialize its abbreviated new drug application approval from the U.S. Food and Drug Administration for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL, 4 g/100 mL and 4 g/50
Syft Technologies announced the release of its next generation Selected Ion Flow Tube Mass Spectrometry technology, Syft Tracer™, at Pittcon 2023.
Syft Technologies Announces Commercial Release of Next Generation SIFT-MS, Syft Tracer™ Read More »
Discover how telehealth is revolutionizing veteran healthcare, providing high-quality care regardless of location with essential use cases like video consultations, remote monitoring and telestroke.
Transforming veteran healthcare: How telehealth is changing the game Read More »
OEMs need to rethink how to deliver scalable, flexible service, especially in economic uncertainty.
How OEMs can budget aftermarket service in a recession Read More »
XNK Therapeutics announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.
New data* presented at the 2023 Osteoarthritis Research Society International World Congress in Denver, Colorado suggest that AKL Therapeutics’ investigational oral osteoarthritis drug APPA** may have a dual effect on senescence.
